Pharma BD Deal Intelligence

Pfizer Inc. / Starna Therapeutics

2026 · Licensing/Option · $2.6B · Complete

Pfizer Inc. entered an exclusive licensing agreement with Starna Therapeutics, a biotechnology company developing RNA medicines designed to enable in vivo therapeutics, covering three pre-IND in vivo CAR-T programs focused on autoimmune diseases. Starna receives $330 million upfront and is eligible for up to $2.3 billion in development and commercial milestones plus royalties on net sales. Pfizer gains exclusive rights outside Greater China to develop, manufacture and commercialize the three programs, along with rights to Starna's technology in inflammation and immunology and in oncology, options to exclusively license compounds created under a separate research collaboration, and an option to expand the territory to include Greater China. Pfizer will lead clinical development outside Greater China, plans to manufacture finished drug product for initial clinical trials at its US facilities, and holds sole and exclusive control over commercialization outside Greater China. The deal marks Pfizer's entry into in vivo CAR-T and broadens its Inflammation & Immunology pipeline.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →